Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis
| Status: | Completed |
|---|---|
| Conditions: | Obesity Weight Loss, Peripheral Vascular Disease, Psoriasis |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Dermatology / Plastic Surgery, Endocrinology |
| Healthy: | No |
| Age Range: | Any - 18 |
| Updated: | 4/2/2016 |
| Start Date: | April 2010 |
| End Date: | April 2011 |
| Contact: | Lawrence F. Eichenfield, MD |
| Email: | leichenfield@rchsd.org |
| Phone: | 858-966-1700 |
Hypothesis 1: Patients with psoriasis will have clinical and laboratory assessments
differing from control patients.
Hypothesis 2: Patients with psoriasis will have laboratory alterations that correlate with
other clinical characteristics of their psoriasis.
differing from control patients.
Hypothesis 2: Patients with psoriasis will have laboratory alterations that correlate with
other clinical characteristics of their psoriasis.
Psoriasis was initially considered an inflammatory condition primarily of the skin. However,
advances in medical knowledge have allowed insight into the wide-ranging systemic effects of
long-term uncontrolled inflammation, thus shifting the concept of psoriasis from an
inflammatory disease restricted to the skin to a systemic process. Adults w/ psoriasis have
higher rates of obesity, hypertension, diabetes, hyperlipidemia and smoking and the
prevalence of each risk factor increases as the extent of psoriasis increases.1 It is
uncertain if any of this relates to a behavioral reaction to having psoriasis or as a
separate part of the disease process. Inflammation has a role in the pathogenesis of
cardiovascular disease most noted by multiple observational studies of psoriasis patients
which demonstrate an increased risk of arterial or venous events, notably myocardial
infarction, cerebrovascular events, pulmonary emboli, cardiovascular death or mortality
overall. Specifically, Gelfand et. al. show an increased relative risk for myocardial
infarction and an increased hazard ratio for mortality in patients with severe psoriasis,
but most notably, show highest risk in younger adult patients. There is a paucity of data on
risks with psoriasis in the pediatric and adolescent age group.
advances in medical knowledge have allowed insight into the wide-ranging systemic effects of
long-term uncontrolled inflammation, thus shifting the concept of psoriasis from an
inflammatory disease restricted to the skin to a systemic process. Adults w/ psoriasis have
higher rates of obesity, hypertension, diabetes, hyperlipidemia and smoking and the
prevalence of each risk factor increases as the extent of psoriasis increases.1 It is
uncertain if any of this relates to a behavioral reaction to having psoriasis or as a
separate part of the disease process. Inflammation has a role in the pathogenesis of
cardiovascular disease most noted by multiple observational studies of psoriasis patients
which demonstrate an increased risk of arterial or venous events, notably myocardial
infarction, cerebrovascular events, pulmonary emboli, cardiovascular death or mortality
overall. Specifically, Gelfand et. al. show an increased relative risk for myocardial
infarction and an increased hazard ratio for mortality in patients with severe psoriasis,
but most notably, show highest risk in younger adult patients. There is a paucity of data on
risks with psoriasis in the pediatric and adolescent age group.
Inclusion Criteria:
Subjects of any race or ethnicity who meet all of the following criteria are eligible for
enrollment into the study:
1. The subject has a diagnosis of typical psoriasis, with or without arthritis, based on
the clinical evaluation by an investigator or a prior diagnosis by a pediatric
dermatologist
2. Persons residing in the US.
3. Subjects 0 to 18 years of age.
4. Subjects/Guardians willing and able to comply with the requirements of the study.
5. Subjects/Guardians willing and able to give informed consent.
6. The subject is in general good health in the opinion of the investigator.
Exclusion Criteria:
1. Over 18 years of age.
2. Subject has had a diagnosis of congenital heart disease.
3. Subject has had any cardiac catheterizations or surgeries.
4. Subject has taken any cardiac medications (calcium channel blockers, beta blockers,
vasotropic medicines) within the past 2 years.
5. Subjects determined to have atypical psoriasis or isolated palmoplantar psoriasis.
6. Subject diagnosed with any other systemic inflammatory disease including atopic
dermatitis, severe acne vulgaris, inflammatory bowel disease, juvenile idiopathic
arthritis, connective tissue disease and other similar conditions.
7. Having autoimmune or immunodeficiency disease.
8. Presence of active systemic fungal, bacterial, or viral infections.
9. Presence of active systemic malignancy.
10. Mental illness or history of drug or alcohol abuse that, in the opinion of the
investigator, would interfere with the participant's ability to comply with study
requirements.
11. Inability or unwillingness of a participant to give written informed consent.
Control Inclusion Criteria:
1. Age up to 18 years.
2. Ability and willingness to provide informed consent.
Control Exclusion Criteria:
1. Over 18 years of age.
2. Subject has had a diagnosis of congenital heart disease.
3. Subject has had any cardiac catheterizations or surgeries.
4. Subject has taken any cardiac medications (calcium channel blockers, beta blockers,
vasotropic medicines) within the past 2 years.
5. Subjects determined to have psoriasis of any type or a family history (first degree
relative) with psoriasis.
6. Subject diagnosed with any other systemic inflammatory disease including atopic
dermatitis, severe acne vulgaris, inflammatory bowel disease, juvenile idiopathic
arthritis, connective tissue disease and other similar conditions.
7. Having autoimmune or immunodeficiency disease.
8. Presence of active systemic fungal, bacterial, or viral infections.
9. Presence of active systemic malignancy.
10. Mental illness or history of drug or alcohol abuse that, in the opinion of the
investigator, would interfere with the participant's ability to comply with study
requirements.
11. Inability or unwillingness of a participant to give written informed consent.
We found this trial at
1
site
Click here to add this to my saved trials
